 Merck & Co. agreed to buy Cubist Pharmaceuticals Inc. for $8.4 billion as the drug giant pushes deeper into antibiotics, an area seeing renewed interest because of the rise of dangerous new infections.. The deal, which also includes the assumption of $1.1 billion in debt, is worth $102 a share, a 37% premium to Friday’s close. The Wall Street Journal and other media had reported on Friday that Merck was nearing a deal for Cubist worth about $100 a share.